Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) strongly supports the committee’s drive to combat the opioid epidemic. While searching for solutions to a widespread problem which has impacted the lives of many across the nation, there has been a consensus that no “one size fits all” solution exists and therefore AMCP believes that a holistic, comprehensive, and multi-stakeholder approach among health care providers and patients is necessary to truly address the opioid epidemic.
The Academy of Managed Care Pharmacy (AMCP) writes in strong opposition to House Bill 4146. House bill 4146 “prohibits a health care plan from modifying an enrollee’s drug coverage in a plan year by (A) increasing out-of-pocket costs for a covered drug; (B) moving a prescription to a more restrictive tier; or (C) removing a prescription drug from a formulary.”
The Academy of Managed Care Pharmacy (AMCP) opposes provisions in Senate Bill 332 that require a medication synchronization program to apply a daily pro-rated cost-sharing rate to prescriptions as determined by the prescriber and pharmacist which would abrogate existing health insurance plan contract terms with the parties.
The Academy of Managed Care Pharmacy (AMCP) opposes provisions in Assembly Bill 4306 that require a medication synchronization program to apply a daily pro-rated cost-sharing rate to prescriptions as determined by the health care practitioner and pharmacist which would abrogate existing health plan contract terms with the parties.
AMCP Submits Letter to Illinois Senate Committee Opposing House Bill 4146 Which Prohibits Formulary Changes During a Plan Year.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of H.R. 3545 – the “Overdose Prevention and Patient Safety Act”. As you know, H.R. 3545 has bipartisan support and was introduced by Reps. Markwayne Mullin (R-OK), Earl Blumenauer (R-OR), Jim Renacci (R-OH), Buddy Carter (R-GA) and Pat Meehan (R-PA).
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate File 75. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) strongly supports House Bill 1716. House Bill 1716 would allow carriers to request information for individual patient case reviews for determining medical necessity of a prescription, enhancing or coordinating patient care, or for assisting the treating provider’s clinical decision making, at the discretion of the Secretary of the Department of Health.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the notice titled “Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter” released on February 1, 2018.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 350. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4524. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) writes to support and express concerns with specific provisions of Senate Bill 92. This legislation would regulate biological products and substitution of interchangeable biological products when dispensed by pharmacists.
